Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.9K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.9K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

648
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
648
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.9K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.9K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

1.7K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.7K
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.3K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic predisposition to unwanted side effects under antidepressants and antipsychotics: a molecular-genetic study of 902 patients over 6 weeks.

European archives of psychiatry and clinical neuroscience·2025
Same author

Genetic determinants of antidepressant and antipsychotic drug response.

European archives of psychiatry and clinical neuroscience·2024
Same author

Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results.

Journal of psychiatric research·2024
Same author

Polypharmacy in psychiatry and weight gain: longitudinal study of 832 patients hospitalized for depression or schizophrenia, along with data of 3180 students from Europe, the U.S., South America, and China.

European archives of psychiatry and clinical neuroscience·2024
Same author

Analysis of genetic diversity in patients with major psychiatric disorders versus healthy controls: A molecular-genetic study of 1698 subjects genotyped for 100 candidate genes (549 SNPs).

Psychiatry research·2024
Same author

Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine ("Ecstasy") induced cytoskeletal damage.

Journal of neural transmission (Vienna, Austria : 1996)·2022

Related Experiment Video

Updated: Mar 13, 2026

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
07:51

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

11.2K

Predicting relapse after antidepressant withdrawal - a systematic review.

I M Berwian1, H Walter2, E Seifritz1

  • 1Department of Psychiatry, Psychotherapy and Psychosomatics,Hospital of Psychiatry,University of Zurich,Lenggstrasse 31, 8032 Zürich,Switzerland.

Psychological Medicine
|October 28, 2016
PubMed
Summary

Predicting depression relapse after stopping antidepressant medication (ADM) is crucial. Current evidence is weak, lacking validated markers for individual risk, necessitating research into neurobiological predictors.

Keywords:
Antidepressant discontinuationmajor depressive disorderpredictionrelapse

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
A New Method for Inducing a Depression-Like Behavior in Rats
07:57

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

22.5K

Related Experiment Videos

Last Updated: Mar 13, 2026

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
07:51

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

11.2K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.2K
A New Method for Inducing a Depression-Like Behavior in Rats
07:57

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

22.5K

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Depression's recurrent nature significantly contributes to its overall burden.
  • High relapse rates occur after discontinuing antidepressant medication (ADM), but individual risk varies.
  • Identifying predictors of relapse could personalize treatment and improve long-term depression management.

Purpose of the Study:

  • To systematically review and identify predictors of relapse in major depressive disorder (MDD) patients after discontinuing ADM.
  • To assess the strength of evidence for existing relapse predictors.
  • To highlight the need for validated markers for individualized discontinuation decisions.

Main Methods:

  • Systematic literature search in PubMed using comprehensive search terms related to depression, relapse, prediction, and antidepressant discontinuation.
  • Inclusion criteria: patients aged 18-65 with MDD, remitted on ADM, followed for ≥6 months post-discontinuation.
  • Analysis of 13 studies (nine independent samples) investigating relapse predictors.

Main Results:

  • Multiple potential predictors were identified, including markers of treatment response and prior episode history.
  • Existing evidence for these predictors is currently weak.
  • No established or validated markers exist for predicting individual relapse risk after antidepressant cessation.

Conclusions:

  • Current evidence is insufficient to guide individualized antidepressant discontinuation decisions beyond general recurrence risk.
  • There is a significant need for research into neurobiological markers to predict individual relapse risk.
  • Focusing on treatment discontinuation is essential for developing personalized depression management strategies.